What the FDA labels say about taking them together
Everolimus and voriconazole
Everolimus's FDA label (Zortress) of February 12, 2026 names voriconazole in its drug interactions section, and voriconazole's label names everolimus too. The everolimus label: “Concurrent treatment with strong inhibitors and inducers of CYP3A4 is not recommended.”
Check it at the source: the everolimus FDA label on DailyMed (effective June 1, 2026, Novartis Pharmaceuticals Corporation); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the everolimus label say about voriconazole?
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), drug interactionsConcurrent treatment with strong inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) and inducers (e.g., rifampin, rifabutin) of CYP3A4 is not recommended.
Zortress label (Novartis Pharmaceuticals Corporation, February 12, 2026), warnings and precautionsInhibitors and Inducers of CYP3A4 Coadministration of Zortress with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, boceprevir, telaprevir) or strong CYP3A4 inducers (e.g., rifampin, rifabutin) is not recommended without close monitoring of everolimus whole blood trough concentrations [see Drug Interactions (7)].
Source: FDA drug label (Zortress, NDA021560), Novartis Pharmaceuticals Corporation, effective February 12, 2026 (SPL set e082a024-7850-400b-a5c2-2a140612562a), via openFDA
Source: FDA drug label (Afinitor), Novartis Pharmaceuticals Corporation, effective June 1, 2026 (SPL set 2150f73a-179b-4afc-b8ce-67c85cc72f04), via openFDA; the full label on DailyMed
What does the voriconazole label say about everolimus?
Voriconazole label, drug interactionsEverolimus (CYP3A4 Inhibition) Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased Concomitant administration of voriconazole and everolimus is not recommended.
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Everolimus (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Recommendations for Drug Dosage Adjustment/Comments: Concomitant administration of Voriconazole for injection and everolimus is not recommended.
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Everolimus | Voriconazole | |
|---|---|---|
| Labeled for | Breast cancer, Seizures and epilepsy, Organ transplant rejection | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $26.32 per tablet 10 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | A presentation being discontinued | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once